MedPath

FDA Revokes Emergency Use Authorization for Sotrovimab

• The FDA has revoked the Emergency Use Authorization (EUA) for sotrovimab due to the expiration of all manufactured lots under EUA 100. • GSK requested the EUA revocation on November 22, 2024, as sotrovimab was not authorized for use against non-susceptible SARS-CoV-2 variants. • The FDA determined that revoking the authorization is appropriate to protect public health and safety, considering variant susceptibility.

The U.S. Food and Drug Administration (FDA) has revoked the Emergency Use Authorization (EUA) for sotrovimab, a monoclonal antibody previously authorized for the treatment of COVID-19. The decision, effective December 13, 2024, follows a request from GSK on November 22, 2024, to revoke the EUA.
The revocation is based on the fact that all lots of sotrovimab manufactured and labeled for use under EUA 100 have expired. Furthermore, sotrovimab was not authorized for use in regions where infection was likely caused by SARS-CoV-2 variants against which the drug is not susceptible, based on available data regarding variant susceptibility and regional variant frequency.
The FDA has determined that it is appropriate to revoke the authorization to protect public health and safety. This decision reflects the agency's ongoing assessment of available scientific information and the evolving landscape of SARS-CoV-2 variants.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Revokes Emergency Use Authorization for Hydroxychloroquine in COVID-19 Treatment

The FDA has revoked the Emergency Use Authorization for hydroxychloroquine and chloroquine to treat COVID-19, citing ineffectiveness based on emerging data.
The decision was influenced by data showing the drugs are unlikely to be effective against COVID-19 and pose potential cardiac risks.

FDA Revokes Emergency Use Authorization for Bebtelovimab Due to Expired Lots and Variant Resistance

The FDA revoked the Emergency Use Authorization (EUA) for bebtelovimab on December 5, 2024, following a request from Lilly due to the expiration of all manufactured lots.
Bebtelovimab was no longer authorized for use in regions where SARS-CoV-2 variants demonstrated resistance, based on available susceptibility data and variant frequency.

FDA Revokes Emergency Use Authorizations for COVID-19 Antibody Treatments Evusheld and REGEN-COV

The FDA has revoked the Emergency Use Authorization (EUA) for AstraZeneca's Evusheld due to the expiration of all distributed lots and high prevalence of non-susceptible variants.
Regeneron requested the FDA revoke the EUA for REGEN-COV because all manufactured lots have expired, and the company no longer intends to offer the product in the United States.

FDA Revokes Emergency Use Authorizations for Four COVID-19 Monoclonal Antibody Products

The FDA has revoked the Emergency Use Authorizations (EUAs) for four monoclonal antibody products used in the U.S. government's COVID-19 response.
The revoked EUAs include treatments from Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron Pharmaceuticals due to the rise of resistant SARS-CoV-2 variants.

FDA Revokes Authorization of GSK and Vir's Sotrovimab Due to BA.2 Inefficacy

The FDA has fully revoked the emergency use authorization for GlaxoSmithKline and Vir Biotechnology's sotrovimab due to its reduced efficacy against the Omicron sub-variant BA.2.
Sotrovimab initially received EUA based on Phase III trial data showing an 85% reduction in hospitalization or death risk for high-risk COVID-19 patients.

FDA Revokes Emergency Use Authorizations for Four Monoclonal Antibody Treatments Due to Variant Resistance

The FDA has revoked the Emergency Use Authorizations (EUAs) for four monoclonal antibody (mAb) products previously used to treat COVID-19 due to persistent resistance from circulating SARS-CoV-2 variants.
These mAbs have not been authorized for patient administration for over a year because of the high prevalence of SARS-CoV-2 variants against which they are ineffective.

FDA Revokes Emergency Use Authorization for Evusheld Due to Variant Ineffectiveness

The FDA has revoked the emergency use authorization for Evusheld (tixagevimab/cilgavimab) in the U.S. due to its reduced efficacy against emerging SARS-CoV-2 variants.
Recent data indicates that Evusheld is unlikely to be effective against current dominant variants, such as XBB.1.5, which account for the majority of new infections.

FDA Withdraws Original COVID-19 Vaccine Authorization, Focuses on Bivalent Boosters

The FDA has withdrawn the emergency use authorizations for the original Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines.
Updated bivalent vaccines targeting original and Omicron BA.4/BA.5 strains are now authorized for all doses in individuals six months and older.

FDA Restricts Sotrovimab Use Due to Omicron BA.2 Variant Resistance

The FDA has suspended the authorization of GlaxoSmithKline and Vir Biotechnology's sotrovimab in regions where the Omicron BA.2 subvariant is dominant, citing inefficacy.
Sotrovimab, a monoclonal antibody, was previously authorized for treating high-risk COVID-19 patients but shows reduced effectiveness against the BA.2 subvariant.

FDA Revokes Emergency Use Authorization for Bamlanivimab Monotherapy Against COVID-19

The FDA revoked the EUA for bamlanivimab monotherapy due to increasing SARS-CoV-2 variants resistant to the treatment, raising the risk of treatment failure.
Data from the CDC showed a significant increase in resistant variants, from 5% in mid-January to approximately 20% in mid-March 2021.

Reference News

[1]
FDA Revokes EUA for Sotrovimab for the Treatment of COVID-19
drugs.com · Apr 9, 2025

FDA revoked EUA for sotrovimab on GSK's request due to expired lots and nonsusceptible SARS-CoV-2 variants.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy